BEAT

HeartBeam's stock price has decreased significantly, trading at $0.8901 as of May 9, 2026, down 62.8% since the beginning of the year. Key events include FDA clearance of its 12-lead ECG synthesis software in December 2025, first patient enrollments in the ALIGN-ACS pilot study in March 2026, reporting fourth quarter and full year 2025 results in March 2026, closing an underwritten public offering of 12,500,000 shares in April 2026, and announcing a commercial agreement with Atelier Health in May 2026.